Inam H^, Rao Y^, Pritchard JR. Pairwise tests for conditional selection use evolutionary logic to predict intrinsic drug resistance to ALK alterations. Currently available on biorxiv. Under review at PLOS Computational Biology. ^PSU Trainee.
Bruno PM, Lu M^, Dennis K^, Inam H^, Moore C^, Shehee J^, Elledge SJ, Hemann MT, Pritchard JR. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is Topoisomerase II poisoning. Online at Proceedings of the National Academy of Sciences. ^PSU Trainee
Leighow SM^*, Liu C^*, Inam H^, Zhao B^, Pritchard JR. Multi-scale predictions of drug resistance epidemiology suggest a new design principle for rational drug design. Currently available on biorxiv. Accepted at Cell Reports.* Co-First authors,^PSU Trainee.
Zhao B^, Pritchard JR. Evolution of the nonsense-mediated decay (NMD) pathway is associated with decreased cytolytic immune infiltration. PLOS Computational Biology 15(10): e1007467 2019. ^PSU Biomedical Engineering Trainee.
Leighow SM^, Pritchard JR. The risks of perpetuating an evolutionary arms race in drug discovery. Evolution, Medicine, and Public Health. Volume 2019, Issue 1, 2019, 64:65. ^PSU Trainee.
Schmitt MW*, Pritchard JR*, Leighow SM^, Aminov BI, Beppu L, Kim DS, Hodgson JG, Rivera VM, Loeb LA, Radich JP. Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clinical Cancer Research. 24 (21) 5321-5334 2018. *Co-First and Co-Corresponding Author, ^PSU Trainee.
Gozgit JM, Chen TH, Song Y, Wardwell S, Wang F, Cai J, Li H, Edgren H, Rivera VM, Pritchard JR. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget. 9 (51), 29564 2018.
Laencina L, Dubois V, Le Moigne V, Viljoen A, ,Pritchard J, Bernut A, Piel L, Anne-Laure Roux, Gaillard JL, Lombard B, Loew, Rubin EJ, Brosch R, Kremer L, Herrmann JL, Girard-Misguich F. Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus. Proceedings of the National Academy of Sciences.
Bruno PM,Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, and Hemann MT. A subset of platinum containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nature Medicine 23, 461-471 2017.
Rock JM, Hopkins FF, Chavez A, Diallo M, Chase MR, Gerrick ER, Pritchard JR, Church GM, Rubin EJ, Sassetti CM, Schnappinger D, and Fortune SM. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nature Microbiology 2, 16274 2017
Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Douglas A Lauffenburger, Michael T Hemann Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 2016 165 (1), 234-246.
Zhao B, Pritchard JR. Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes. PLOS Genetics 2016 12 (6), e1006081.
Baker T, Nerle S, Pritchard JR, Zhao B, Rivera VM, Garner A, Gonzalvez F, Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget 6 (32), 32646 2015.
Zhao B, Pritchard JR*, Lauffenburger DA*, Hemann MT*. Minimization of intra-tumoral heterogeneity through rationally designed combination therapy. Cancer Discovery. 2014 4 (2), 166-174 *co-corresponding author.
Meacham CE, Lawson L, Fenouli N, Pritchard JR, Zuber J, Young R, and Hemann MT. An in vivo genome-scale RNAi screen reveals PHF6 as a lineage specific regulator of leukemia maintenance. Genes & Development 29 (5), 483-488 2015.
Pritchard JR, Chao MC, Abel S, Davis BM, Baranowski C, Zhang Y, Rubin EJ, and Waldor MK. ARTIST: High-resolution genome-wide assessment of fitness using transposon-insertion sequencing. PLOS Genetics 10 (11), e1004782 2014
Wang J, Pritchard JR, Kreitmann L, Montpetit A, Behr MA, Disruption of Mycobacterium avium subsp, paratuberculosis-specific genes impairs in vivo fitness. BMC Genomics 2014 15(1),1.
Chao MC, Pritchard JR, Zhang YJ, Rubin EJ, Livny J, Davis BM, Waldor MK. High resolution definition of the Vibrio cholerae essential gene set with Hidden Markov Model-based analyses of TnSeq data. Nucleic Acids Research Oct; 41(19): 9033–9048 2013
Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA. Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst. 2013 Jul 4;9(7):1604-19. Invited as part of a special issue on network approaches in systems biology.
Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining genetic principles of combination chemotherapy. Proceedings of the National Academy of Sciences. 2013 Jan 8;110(2):E170-9
Pritchard JR, Lauffenburger DA, and Hemann MT. Understanding resistance to combination chemotherapy. Drug Resistance Updates November. 2012 Oct;15(5-6):249-57.
Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nature Chemical Biology. 2011 Feb;7(2):92-100.
Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. BCL-2 family genetic profiling reveals microenvironment-specific determinants of therapeutic response. Cancer Research. 2011 Sep 1;71(17):5850-8
Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Molecular Cancer Therapeutics. 2009 Aug;8(8):2183-92.
Cosgrove BD, Cheng C, Pritchard JR, Stolz DB, Lauffenburger DA, Griffith LG. An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-alpha. Hepatology. 2008 Jul;48(1):276-88.
Published Proceedings at major Clinical Conferences — Industry
JR Pritchard, MW Schmitt, LA Loeb, JP Radich, VM Rivera. Analysis of the sub-clonal origins of ponatinib resistance. Blood, Oral presentation ASH annual meeting 2016.
VM Rivera, S Branford, FE Nicolini, JR Pritchard, JM Gozgit, W Kern, D Milojkovic, S Claudiani, MC Muller, SK Tantravahi, MW Deininger, M Heinrich, S Soverini, M Baccarani, JP Radich, E Jabbour, JE Cortes, G Etienne, T Haferlach. A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients. Blood 126:2790 2015
MW Schmitt, JR Pritchard, JG Hodgson, VM Rivera, BI Aminov, L Beppu, LA Loeb, JP Radich. Emergence of sub-clonal drug resistance mutations during CML therapy. Blood 126 (23) 478 2015
J Pritchard, S Lustgarten, JG Hodgson, M Baccarani, JE Cortes Analysis of the relationship between dose and BCR-ABL halving time in CP-CML patients treated with Ponatinib or Imatinib. Haematologica 100, 448-449
MC Heinrich, JG Hodgson, M von Mehren, GD Demetri, JA Fletcher, JR Pritchard et al. Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST). ASCO Annual Meeting Proceedings 33 (15_suppl), 10517 2015
VM Rivera, JR Pritchard, F Gonzalvez, T Baker, JM Gozgit, G Hodgson, et al. Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events Blood 124 (21), 1783-1783 2014
JR Pritchard, S Lustgarten, G Hodgson, M Baccarani, JE Cortes, et al. High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib. Blood 124 (21), 3153-3153 2014
JR Pritchard, S Lustgarten, G Hodgson, M Baccarani, JE Cortes, et al. High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial. Clinical Lymphoma Myeloma and Leukemia 15, S212 2014